130 related articles for article (PubMed ID: 29552770)
41. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
[TBL] [Abstract][Full Text] [Related]
42. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
43. [Promising new drugs for gynecological cancer].
Yakushiji M; Sugiyama T; Ushijima K
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1932-7. PubMed ID: 9350238
[TBL] [Abstract][Full Text] [Related]
44. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
45. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
Zhang BY; Wang YM; Gong H; Zhao H; Lv XY; Yuan GH; Han SR
Int J Clin Exp Pathol; 2015; 8(1):25-37. PubMed ID: 25755690
[TBL] [Abstract][Full Text] [Related]
46. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.
Tsvetkova D; Ivanova S
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458666
[TBL] [Abstract][Full Text] [Related]
47. Paclitaxel in germ cell cancer.
Motzer RJ; Chou TC; Schwartz L; Bosl GJ; Bajorin DF; Hutter H
Semin Oncol; 1995 Jun; 22(3 Suppl 6):12-5. PubMed ID: 7597428
[TBL] [Abstract][Full Text] [Related]
48. Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.
Tam KF; Ng TY; Tsang PC; Li CF; Ngan HY
J Soc Gynecol Investig; 2006 Oct; 13(7):518-22. PubMed ID: 16979354
[TBL] [Abstract][Full Text] [Related]
49. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death.
Dhanalakshmi S; Agarwal P; Glode LM; Agarwal R
Int J Cancer; 2003 Sep; 106(5):699-705. PubMed ID: 12866029
[TBL] [Abstract][Full Text] [Related]
50. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
51. [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
Sedláková I; Tosner J; Cervinka M; Brigulová K; Rezác A; Spacek J; Laco J; Skapinec P
Ceska Gynekol; 2011 Jun; 76(3):184-9. PubMed ID: 21838147
[TBL] [Abstract][Full Text] [Related]
52. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
53. Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Untch M; Sevin BU; Perras JP; Angioli R; Baibl A; Nguyen HN; Hightower RD; Averette HE
Gynecol Oncol; 1992 Nov; 47(2):172-8. PubMed ID: 1468695
[TBL] [Abstract][Full Text] [Related]
54. [Paclitaxel containing chemotherapeutic regimens in first line and reintroduced palliative treatment of metastatic cervical cancer].
Kullmann T; Sipőcz I; Agyemang-Prempeh K; Barna O; Pintér T
Orv Hetil; 2018 Jun; 159(24):974-977. PubMed ID: 29888659
[TBL] [Abstract][Full Text] [Related]
55. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
56. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.
Liu B; Han L; Liu J; Han S; Chen Z; Jiang L
Int J Nanomedicine; 2017; 12():955-968. PubMed ID: 28203075
[TBL] [Abstract][Full Text] [Related]
57. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
58. [Quantitative determination of dose-response relations of taxol and cisplatin in ovarian cancer cells with a bioassay in comparison with cytomorphology].
Köchli OR; Landolt U; Schär G; Sevin BU; Haller U
Gynakol Geburtshilfliche Rundsch; 1994; 34(2):79-86. PubMed ID: 7950442
[TBL] [Abstract][Full Text] [Related]
59. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
[TBL] [Abstract][Full Text] [Related]
60. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
